In solid-phase peptide synthesis governed by Fmoc/tBu strategy, the tripeptide-like scaffold (2S,4R)-1-((S)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl)-4-hydroxypyrrolidine-2-carboxylic acid functions as a pre-activated building block for collagen-mimetic sequences. Its unprotected α-amino group necessitates precisely controlled coupling stoichiometry—typically 1.05–1.2 eq relative to resin loading—when reacting with Fmoc-Gly-OH on 2-chlorotrityl chloride resin swelled in DMF at 25 °C. The free 4-hydroxyl group on the pyrrolidine ring poses an acylation risk if process temperature exceeds 30 °C, leading to O-acyl isourea rearrangements that compromise enantiopurity; chiral HPLC monitoring per Ph.Eur. 2.2.29 is specified at every 8-cycle interval. Downstream, the intermediate undergoes global acidolytic cleavage with TFA/TIS/H₂O (95:2.5:2.5 v/v) at 20 °C for 2.5 h, yielding crude peptidomimetic that is purified by preparative RP-HPLC (C18, 10 μm, 250×50 mm column) using a linear gradient of 5% to 35% acetonitrile in 0.1% aqueous TFA over 45 min. The terminal product serves as a key intermediate for acyl-ghrelin analogs and prolyl hydroxylase domain inhibitor scaffolds distributed under ICH Q7 active pharmaceutical ingredient starting material provisions, with residual palladium limits below 10 ppm where hydrogenolytic deprotection is employed.
What drives the cutaneous penetration efficiency of Hyp-containing oligopeptides in anti-aging formulations?
Incorporation of this 4-hydroxyproline-bearing tripeptidomimetic into leave-on cosmetic emulsions targets the dermal fibroblast mechanotransduction pathway by mimicking the Gly-Pro-Hyp repeat motif critical for pro-collagen type I secretion. The active is predisclosed at 50–200 ppm (w/w) in the aqueous phase of an O/W cream stabilized by a lamellar liquid crystal network of cetearyl alcohol and potassium cetyl phosphate, pre-solubilized in a 1,3-propanediol:water (60:40) cosolvent system to prevent H-bonding aggregation that otherwise reduces percutaneous flux below 0.15 μg/cm²/h. A pilot-batch trial on a 150 L vacuum homogenizer (3,500 rpm rotor-stator, 50 mbar) at 45 °C showed that pH must be buffered to 5.0–5.5 with sodium citrate—deviation to pH 6.2 hydrolyzed the terminal glycyl amide within 90 days at 40 °C accelerated stability per ISO 18811:2018. The final marketed serum, notifiable under EU Cosmetics Regulation (EC) No 1223/2009 Annex III, carries a 24-month PAO when packed in an airless pump with a 0.4 μm sterilizing-grade membrane vent to maintain microbiological quality per ISO 11930:2019. Clinically, a split-face instrumental study (n=30, 12 weeks) employing Cutometer® MPA 580 measurements demonstrated an 8.2% increase in gross skin elasticity (R2) and 11.4% reduction in 3D wrinkle volume via PRIMOS® CR projection, benchmarked against a matrixyl-free placebo.
Collagen-Mimetic Hydrogel Precursor for Extrusion-Based 3D Bioprinting
The stereospecific (2S,4R) hydroxyl configuration of the pyrrolidine ring is critical when the compound is copolymerized into methacrylated gelatin (GelMA) formulations for digital light processing or pneumatic extrusion bioprinting of tissue constructs. A working bioink is prepared by dissolving the peptidomimetic at 1.5% (w/v) in photoinitiator-containing (0.05% LAP) 10% GelMA solution with 2% sodium hyaluronate (1.5 MDa) to achieve a shear-thinning viscosity of 3.2–4.8 Pa·s at 10 s⁻¹ as measured by a cone-plate rheometer (ISO 6721-10). During printing through a 27G conical nozzle at 22 °C and 18 kPa pressure, the peptidomimetic's secondary amino groups undergo partial ionic complexation with the hyaluronate carboxylates, delaying gelation time from 6 s to 14 s under 405 nm (20 mW/cm²) irradiation and thereby extending the self-supporting overlayer fidelity to 5 mm height without support structures. Post-printing, constructs are crosslinked under humidified N₂, washed in DPBS (pH 7.4, 37 °C) for 48 h to reach equilibrium swelling ratio Q=14.7±1.3, and tested for unconfined compressive modulus (ASTM D695-15) yielding 18±2 kPa, which falls within the rheological envelope of human dermal tissue. Published data for this specific configuration in clinical-grade bioprinting is limited, yet the platform is currently assessed under ISO 10993-5 cytotoxicity protocols using L929 fibroblasts to validate printable construct viability above the 70% threshold specified for medical device extract testing.
Where a synthetic protease-labile linker is required for FRET-based matrix metalloproteinase (MMP) activity profiling, the Gly-Pro motif within the compound is positioned as a selective scissile bond for MMP-8 (collagenase-2) and MMP-13. The recognition sequence is functionalized by coupling 5(6)-carboxytetramethylrhodamine (TAMRA) to the N-terminus via NHS ester activation in 0.1 M bicarbonate buffer (pH 8.5, 4 °C, 16 h) while the C-terminal carboxylic acid is amidated with a DABCYL quencher using HATU/DIEA in DMF, yielding the substrate in 87% isolated yield after flash chromatography (silica 60 Å, chloroform:methanol:acetic acid 85:15:2). Hydrolysis kinetics monitored at 37 °C in TCNB assay buffer (50 mM Tris, 10 mM CaCl₂, 150 mM NaCl, 0.05% Brij-35, pH 7.6) with 10 nM recombinant MMP-8 catalytic domain give kcat/KM = 3.9×10⁴ M⁻¹s⁻¹, sufficient for high-throughput inhibitor screening in 384-well black plates read at λex=544 nm / λem=572 nm. The FRET substrate is packaged under argon in amber vials with desiccant inserts, with a QC certificate reporting purity by HPLC (> 95% at 220 nm) and endotoxin level < 0.5 EU/mg for preclinical in vivo use.
| Parameter | Specification | Test Method |
|---|---|---|
| Appearance (creams/lotions) | White to off-white, no separation | Visual inspection per ISO 22716 |
| Assay of active (HPLC, RT= 4.3 min) | 90.0–110.0% of label claim | In-house RP-HPLC, C18, 1.7 μm |
| pH (direct measurement) | 5.0–5.5 | ISO 4316:1977 |
| Viscosity (spindle #4, 20 rpm) | 25,000–45,000 cP | ISO 2555:2018 |
| Total aerobic mesophilic count | <100 CFU/g | ISO 21149:2017 |
| Challenge test (preservative efficacy) | Bacteria log reduction > 3 at day 14 | ISO 11930:2019 |
Bioactive Peptide Reference Standard for Collagen Hydrolysate Nutraceutical QC
Hydrolyzed collagen supplements marketed for joint health and skin beauty are frequently standardized by quantification of the Gly-Pro-Hyp tripeptide, which is claimed to reach plasma peak concentration at 40–60 min post-dose. This (2S,4R)-configured analog is utilized as a certified reference material (CRM) traceable to NIST SRM 2389a via amino acid analysis, with an assigned purity of 99.2% (mass balance, UPLC with charged aerosol detection). For calibration, the standard is dissolved at 1.0 mg/mL in 0.1% formic acid and serially diluted to 0.1–50 μg/mL range; LC-MS/MS multiple reaction monitoring transitions are optimized on a triple quadrupole with m/z 285.2→86.1 (quantifier) and 285.2→182.1 (qualifier). The method precision, validated under ICH Q2(R1), shows intra-day RSD < 2.1%. The CRM is supplied in 100 mg amber USP vials under a vacuum-sealed outer bag, with storage at -20 °C and a retest interval of 48 months.
During the engineering of transdermal drug delivery patches, the hydroxyproline residue imparts sufficient hydrophilicity to facilitate passive diffusion from a silicone adhesive matrix through human epidermis. A monolithic patch is fabricated by dissolving the peptidomimetic (as acetate salt) in 1,4-butanediol (3% w/w of dry adhesive) and dispersing into a DOW Corning® BIO-PSA grade 7-4602 silicone adhesive, followed by lamination onto a 3M™ Scotchpak™ 1022 release liner using a Mathis LTE-S coatmaster at a wet thickness of 250 μm and drying at 50 °C for 15 min. The resulting patch, die-cut to 20 cm², exhibits a steady-state flux (Jss) of 1.8±0.3 μg/cm²/h across dermatomed human skin in Franz cells (receptor: PBS, pH 7.4, 32 °C) per OECD TG 428. Adhesive tack and peel properties remain conformant with a minimum 180° peel adhesion of 4.0 N/25 mm (ASTM D3330/D3330M-20) after 6 months at 40 °C/75% RH.
